Treatment of metastatic colorectal cancer with or without bevacizumab: Can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab?

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 12, 2014, Pages 4781-4786

  Dirican, Ahmet ^a   Varol, Umut ^a   Kucukzeybek, Yuksel ^a   Alacacioglu, Ahmet ^a   Erten, Cigdem ^a   Somali, Isil ^b   Can, Alper ^a   Demir, Lutfiye ^a   Bayoglu, Ibrahim Vedat ^a   Akyol, Murat ^a   Yildiz, Yasar ^a   Koyuncu, Betul ^a   Coban, Eyup ^a   Tarhan, Mustafa Oktay ^b  

^a IZMIR KATIP CELEBI UNIVERSITY   (Turkey)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Bevacizumab; Metastatic colorectal cancer; Neutrophil to lymphocyte ratio; Response to therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAMPTOTHECIN; CAPECITABINE; DEOXYCYTIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PLATINUM COMPLEX;

ADENOCARCINOMA; ADULT; AGED; ANALOGS AND DERIVATIVES; CANCER STAGING; COLORECTAL NEOPLASMS; FEMALE; FOLLOW UP; HUMAN; LYMPHOCYTE; MALE; MIDDLE AGED; MORTALITY; NEUTROPHIL; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPHILS; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84904667389     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.12.4781     Document Type: Article

References (35)

1. Abajo A, Boni V, Lopez I, et al (2012). Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients. Br J Cancer, 107, 287-90.
2. Algire GH, Chalkley HW, Legallais FY, Park HD (1945). Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst, 6, 73-85.
3. Botta C, Barbieri V, Ciliberto D, et al (2013). Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther, 14, 469-75.
4. Cedrés S, Torrejon D, Martinez A, et al (2012). Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol, 14, 864-9.
5. Cihan YB, Ozturk A, Mutlu H (2014). Relationship between prognosis and neutrophil: lymphocyte and platelet:lymphocyte ratios in patients with malignant pleural mesotheliomas. Asian Pac J Cancer Prev, 15, 2061-7.
6. Clarke S, Burge M, Cordwell C, et al (2013). An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab (Avastin™). BMC Cancer, 13, 120.
7. De Gramont A, Figer A, Seymour M, et al (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 18, 2938-47.
8. Ducreux J, Bennouna M, Hebbar M, et al (2007). Efficacy and safety findings from a randomized phase III study of capecitabine and oxaliplatin vs infusion 5-FU/LV+O (FOLFOX-6) for metastatic colorectal cancer (MCRC) (abstract). J Clin Oncol, 25, 170.
9. Eisenhauer EA, Therasse P, Bogaerts J, et al (2009).New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47.
10. Ferrara N, Kerbel RS (2005). Angiogenesis as a therapeutic target. Nature, 438, 967-74.
11. Formica V, Massara MC, Portarena I, et al (2009). Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients. Cancer Biomark, 5, 167-75.
12. Fuchs CS, Marshall J, Mitchell E, et al (2007). Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol, 25, 4779-86.
13. Fuchs CS, Marshall J, Barrueco J, et al (2008). Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol, 26, 689-90.
14. Giantonio BJ, Catalano PJ, Meropol NJ, et al (2007). Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol, 25, 1539-44.
15. Gunduz S, Mutlu H, Uysal M, Coskun HS, Bozcuk H (2014). Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors. Asian Pac J Cancer Prev, 15, 3801-4.
16. Gyanchandani R, Sano D, Ortega Alves MV, et al (2013). Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma. Oral Oncol, 49, 761-70.
17. Hurwitz HI, Fehrenbacher L, Novotny W, et al (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350, 2335-42.
18. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al (2005). Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol, 23, 3502-8.
19. Hochster HS, Hart LL, Ramanathan RK, et al (2008). Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol, 26, 3523-9.
20. Ishizuka M, Nagata H, Takagi K, et al (2012). Clinical significance of tumor pathology for postoperative survival of patients undergoing surgery for stage IV colorectal cancer. Anticancer Res, 32, 3291-7.
21. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol, 23, 3697-705.
22. Kacan T, Babacan NA, Seker M, et al (2014). Could the neutrophil to lymphocyte ratio be a poor prognostic factor for non small cell lung cancers? Asian Pac J Cancer Prev, 15, 2089-94.
23. Kemal Y, Yucel I, Ekiz K, et al (2014). Elevated serum neutrophil to lymphocyte and platelet to lymphocyte ratios could be useful in lung cancer diagnosis. Asian Pac J Cancer Prev, 15, 2651-4.
24. Macedo LT, da Costa Lima AB, Sasse AD, et al (2012). Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer, 13, 89.
25. Ozdemir Y, Akin ML, Sucullu I, Balta AZ, Yucel E (2014). Pretreatment neutrophil/lymphocyte ratio as a prognostic aid in colorectal cancer. Asian Pac J Cancer Prev, 15, 2647-50.
26. Pectasides D, Papaxoinis G, Kalogeras KT, et al (2012). XELIRIbevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. BMC Cancer, 12, 271.
27. Price TJ, Zannino D, Wilson K, et al (2012). Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. Ann Oncol, 23, 1531-6.
28. Proctor MJ, McMillan DC, Morrison DS, et al (2012). A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer, 107, 695-9.
29. Saltz LB, Clarke S, Díaz-Rubio E, et al (2008). Bevacizumab in combination with oxaliplatin-based chemotherapy as firstline therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol, 26, 2013-9.
30. Stathopoulos GP, Batziou C, Trafalis D, et al (2010). Treatment of colorectal cancer with and without bevacizumab: a phase III study. Oncology, 78, 376-81.
31. Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A (2013). Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev, 14, 5237-42.
32. Uygun K, Bilici A, Kaya S, et al (2013). XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions. Asian Pac J Cancer Prev, 14, 2283-8.
33. Van Cutsem E, Rivera F, Berry S, et al (2009). First BEAT investigators. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol, 20, 1842-7.
34. Wang S, Zhang Z, Fang F, et al (2011). The neutrophil/ lymphocyte ratio is an independent prognostic indicator in patients with bone metastasis. Oncol Lett, 2, 735-740.
35. Zheng YB, Zhao W, Liu B, et al (2013). The blood neutrophil-tolymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pac J Cancer Prev, 14, 5527-31.